Henderson I C
Breast Evaluation Center, Dana-Farber Cancer Institute, Boston, MA 02115.
Breast Cancer Res Treat. 1989 Oct;14(1):3-22. doi: 10.1007/BF01805971.
After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much benefit can be achieved, and when (if ever) the risk/benefit ratio may not favor this approach. The results of these trials, and some trials still in progress, are summarized, and the current understanding of the role of systemic adjuvant therapy for breast cancer is reviewed.
在超过100项已报道的乳腺癌全身辅助治疗随机试验之后，很明显这种治疗将显著延长复发时间和生存时间，至少在某些患者亚组中是这样。但对于哪些亚组、哪些治疗方法、能实现多大益处以及何时（如果有的话）风险/益处比可能不支持这种方法，尚未达成完全一致。总结了这些试验以及一些仍在进行中的试验结果，并对目前对乳腺癌全身辅助治疗作用的理解进行了综述。
